Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Clinical Study of Dual Specificity CD19 and CD22 Chimeric Antigen Receptor T Cell Therapy in Relapsed or Refractory Lymphoma

Trial Profile

A Phase I Clinical Study of Dual Specificity CD19 and CD22 Chimeric Antigen Receptor T Cell Therapy in Relapsed or Refractory Lymphoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 21 Feb 2019

At a glance

  • Drugs LCAR L10D (Primary)
  • Indications B-cell lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 10 Feb 2019 Planned number of patients changed from 12 to 9.
    • 10 Feb 2019 Planned initiation date changed from 18 Sep 2018 to 18 Feb 2018.
    • 27 Jul 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top